RecruitingPhase 2NCT06563596
Epco, Zanu, Ritux for R/R FL or MZL
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Reid Merryman, MD
- Principal Investigator
- Reid Merryman, MD, MDDana-Farber Cancer Institute
- Intervention
- Zanubrutinib(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (3)
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Collaborators
BeiGene · Genmab
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06563596 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07546760A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234AstraZeneca
- RECRUITINGNCT07528781Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant VolumeGermans Trias i Pujol Hospital
- RECRUITINGPHASE2NCT07029503Swedish Cardiac And Renal Failure Study-1Karolinska Institutet
- RECRUITINGNCT07154823A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic MalignanciesTempus AI
- RECRUITINGNCT07328035Remission in Adults With Severe Asthma in ThailandThammasat University
- RECRUITINGPHASE3NCT07083154GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGPHASE3NCT06911502A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)Celgene